- Home
- DPRO vs APRE Comparison
DPRO vs APRE Comparison
Compare DPRO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- APRE
- Stock Information
- Founded
- DPRO 1998
- APRE 2006
- Country
- DPRO Canada
- APRE United States
- Employees
- DPRO N/A
- APRE N/A
- Industry
- DPRO Aerospace
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DPRO Industrials
- APRE Health Care
- Exchange
- DPRO Nasdaq
- APRE Nasdaq
- Market Cap
- DPRO 13.0M
- APRE 8.2M
- IPO Year
- DPRO N/A
- APRE 2019
- Fundamental
- Price
- DPRO $2.81
- APRE $1.59
- Analyst Decision
- DPRO Strong Buy
- APRE Strong Buy
- Analyst Count
- DPRO 2
- APRE 2
- Target Price
- DPRO $7.00
- APRE $15.50
- AVG Volume (30 Days)
- DPRO 78.0K
- APRE 30.3K
- Earning Date
- DPRO 05-13-2025
- APRE 05-13-2025
- Dividend Yield
- DPRO N/A
- APRE N/A
- EPS Growth
- DPRO N/A
- APRE N/A
- EPS
- DPRO N/A
- APRE N/A
- Revenue
- DPRO $4,559,961.00
- APRE $1,502,581.00
- Revenue This Year
- DPRO $94.01
- APRE N/A
- Revenue Next Year
- DPRO $95.14
- APRE N/A
- P/E Ratio
- DPRO N/A
- APRE N/A
- Revenue Growth
- DPRO 0.10
- APRE 157.63
- 52 Week Low
- DPRO $1.55
- APRE $1.41
- 52 Week High
- DPRO $9.13
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- DPRO 56.44
- APRE 35.54
- Support Level
- DPRO $2.52
- APRE $1.41
- Resistance Level
- DPRO $2.75
- APRE $1.59
- Average True Range (ATR)
- DPRO 0.26
- APRE 0.11
- MACD
- DPRO 0.06
- APRE 0.04
- Stochastic Oscillator
- DPRO 86.91
- APRE 45.88
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.